CDK2 and breast carcinoma: Advanced scRNA-seq and spatial molecular profiling in tumor specimens supported EGFR expression and higher expression of CDK2/cyclin E in TNBC compared with other breast cancer types across primary and post-NAC-resistant TNBCs, and higher levels of co-expression and spatial colocalization in TNBCs.